Skip to main content
. 2017 Aug 4;11:2301–2324. doi: 10.2147/DDDT.S133944

Figure 12.

Figure 12

The 2D (left panel) and 3D (right panel; top view) ligand interactions for selected four hNav1.5 blockers under study. (A, B) Ranolazine, (C, D) lidocaine (E, F), flecainide, and (G, H) CHEMBL2012299. In contrast to ranolazine, lidocaine, and flecainide that bind to the center of the channel close to Phe1760, the binding mode of CHEMBL2012299 shows that it is shifted to the fenestration sites of the hNav1.5 protein.